中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

587 records (took 0.042 seconds)

    APPARATUS AND RELATED METHOD TO FACILITATE TESTING VIA A COMPUTING DEVICE
    91.
    发明申请
    APPARATUS AND RELATED METHOD TO FACILITATE TESTING VIA A COMPUTING DEVICE 有权
    用于通过计算设备进行测试的装置和相关方法

    公开(公告)号：US20160302710A1

    公开(公告)日：2016-10-20

    申请号：US15131699

    申请日：2016-04-18

    Applicant: THE CLEVELAND CLINIC FOUNDATION ,  BIOGEN MA INC.

    Inventor： Jay L. Alberts ,  David D. Schindler ,  Jane Rhodes ,  Wendy Gabel ,  Jim Best

    IPC: A61B5/16 ,  A61B5/00 ,  A61B5/11

    Abstract: This disclosure relates to a device to mechanically and electrically connect with a touch screen computing device, such as a tablet computer. The device can include a platform that can be moved into and out of physical contact with a surface of a touch screen. During engagement with the surface, the moveable platform electrically interacts with the touch screen (e.g., via capacitive coupling) to enable detection by the touch screen of contact members (e.g., pegs) even in the absence of user contact with the pegs.

    Abstract translation: 本公开涉及一种与诸如平板电脑的触摸屏计算设备机械地和电气地连接的设备。 该装置可以包括能够移动进入和离开与触摸屏的表面的物理接触的平台。 在与表面接合期间，即使在没有用户与钉子接触的情况下，可移动平台与触摸屏电触摸（例如，经由电容耦合）也能够通过触摸屏触摸屏进行检测（例如钉）。

    POLYMER CONJUGATES OF INTERFERON BETA-1a AND USES
    93.
    发明申请
    POLYMER CONJUGATES OF INTERFERON BETA-1a AND USES 审中-公开
    干扰素β-1a和用途的聚合物结合

    公开(公告)号：US20160250340A1

    公开(公告)日：2016-09-01

    申请号：US15131233

    申请日：2016-04-18

    Applicant: BIOGEN MA INC.

    Inventor： Blake PEPINSKY ,  Laura RUNKEL ,  Margot BRICKELMAIER ,  Adrian WHITTY ,  Paula HOCHMAN

    IPC: A61K47/48 ,  A61K38/21

    CPC classification number: A61K47/60 ,  A61K38/215 ,  A61K47/59 ,  A61K47/61 ,  Y10S930/142

    Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

    Abstract translation: 包含与包含聚亚烷基二醇部分的聚合物偶联的干扰素β1a的干扰素β多肽，其中所述干扰素-β-1a和聚亚烷基二醇部分被排列成使得干扰素-β-1a相对于另一种治疗形式具有增强的活性 干扰素β（干扰素-β-1b），并且与非结合的干扰素-β-1a相比，其活性没有降低。 本发明的缀合物有用地用于治疗以及非治疗性，例如诊断性应用。

    Neuroprotection in Demyelinating Diseases
    94.
    发明申请
    Neuroprotection in Demyelinating Diseases 审中-公开
    神经保护脱髓鞘疾病

    公开(公告)号：US20160250172A1

    公开(公告)日：2016-09-01

    申请号：US15057836

    申请日：2016-03-01

    Applicant: Biogen MA Inc.

    Inventor： Susan Goelz ,  Katherine Dawson ,  Ralf Linker ,  Ralf Gold

    IPC: A61K31/225 ,  A61K31/785 ,  A61K31/194

    CPC classification number: A61K31/225 ,  A61K9/2072 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/194 ,  A61K31/785 ,  A61K38/02 ,  A61K38/215 ,  A61K2300/00

    Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

    Abstract translation: 提供治疗神经系统疾病的方法，例如由脱髓鞘和/或轴突损失（例如MS）表征的那些。 所述方法包括施用治疗有效量的至少一种式I化合物：其中R 1和R 2独立地选自OH，O-和（C 1-6）烷氧基，或其药学上可接受的盐; 和醋酸格拉默或干扰素-β。

    FACTOR VIII-XTEN FUSIONS AND USES THEREOF
    98.
    发明申请
    FACTOR VIII-XTEN FUSIONS AND USES THEREOF 审中-公开
    因子VIII-XTEN融合及其用途

    公开(公告)号：US20160199454A1

    公开(公告)日：2016-07-14

    申请号：US14912047

    申请日：2014-08-14

    Applicant: BIOGEN MA INC. ,  AMUNIX OPERATING INC.

    Inventor： Tongyao LIU ,  Pei-Yun CHANG ,  John KULMAN ,  Volker SCHELLENBERGER ,  Haiyan JIANG ,  Robert T. PETERS ,  Ekta Seth CHHABRA

    IPC: A61K38/37 ,  A61K9/00 ,  C07K14/00 ,  C07K14/755

    Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.

    Abstract translation: 本发明提供了包含因子VIII（FVIII）多肽和XTEN多肽的嵌合蛋白。 FVIII多肽可以对血管性血友病因子（VWF）具有降低的亲和力。 适当大小的XTEN多肽在特定位置插入FVIII多肽中，以延长FVIII多肽的半衰期。 本发明还包括核苷酸，载体，宿主细胞和使用嵌合蛋白的方法，例如治疗出血疾病和病症。

    USE OF RAMAN SPECTROSCOPY TO MONITOR CULTURE MEDIUM
    100.
    发明申请
    USE OF RAMAN SPECTROSCOPY TO MONITOR CULTURE MEDIUM 审中-公开
    拉曼光谱仪用于监测培养基的使用

    公开(公告)号：US20160025633A1

    公开(公告)日：2016-01-28

    申请号：US14775255

    申请日：2014-03-14

    Applicant: BIOGEN MA INC.

    Inventor： Justin Moretto ,  Brandon Berry ,  Alex Doane

    IPC: G01N21/65

    CPC classification number: G01N21/65 ,  G01J3/44 ,  G01N2201/0446 ,  G01N2201/06113

    Abstract: In one aspect, the disclosure provides a method of defining a Raman signature of a culture component, the method comprising: obtaining a Raman spectrum of a culture component in a non-interfering or minimally-interfering solution, identifying peaks in the Raman spectrum that are associated with the culture component, obtaining a Raman spectrum of a culture medium comprising the culture component, and, removing peaks of the culture component in the Raman spectrum of the culture medium that are distorted compared to the peaks identified in the Raman spectrum of the culture component in a non-interfering or minimally-interfering solution.

    Abstract translation: 一方面，本公开提供了一种限定培养组分的拉曼特征的方法，所述方法包括：获得非干扰或最小干扰溶液中培养组分的拉曼光谱，鉴定拉曼光谱中的峰，其为 与培养组分相关，获得包含培养组分的培养基的拉曼光谱，并且除去与在培养物的拉曼光谱中鉴定的峰相比变形的培养基的拉曼光谱中的培养成分的峰 在非干扰或最小干扰的解决方案中的组件。

Patent Agency Ranking